We’ve all seen it: PTSD that won’t budge. Patients try sertraline or paroxetine—the so-called “gold standards”—and walk away with little more than side effects and a sense of failure.
Enter a new contender: brexpiprazole + sertraline.
A recent Phase 3 randomized controlled trial might finally offer something real for those stuck in the PTSD trenches.
🚨 The Results
In a study across 86 sites with over 550 adults, adding brexpiprazole (2–3 mg) to sertraline (150 mg) led to a 5.6-point greater reduction on the CAPS‑5 (the gold-standard PTSD measure) compared to sertraline + placebo. That’s not a marginal win—it’s a clinically significant shift, especially in a treatment-resistant population.
Responder rates tell the story even clearer:
- 68.5% of patients on the combo had ≥30% reduction in symptoms
- Compared to 48.2% on sertraline alone
- That’s a +20% absolute response rate boost
And the improvements weren’t just short-lived. Benefits held through 12 weeks, even during a post-treatment observation period. No relapse, no rebound—just stability.
🧩 More Than Symptom Checklists
It wasn’t just about PTSD symptoms. This combo also:
- Improved psychosocial functioning (B-IPF scores)
- Reduced anxiety and depression (HADS)
- Lowered global illness severity (CGI-S)
- Helped with all symptom clusters, including reexperiencing, avoidance, and hyperarousal
That’s rare. Most meds in psychiatry hit one or two domains and leave the rest hanging. This one made a dent where it counts: function, resilience, and real-world relief.
⚠️ What About Side Effects?
Brexpiprazole is still an atypical antipsychotic, so there’s baggage. But the trial data suggest it’s relatively well-tolerated:
- Fatigue: 6.8%
- Weight gain: 5.9%
- Somnolence: 5.4%
- Discontinuation due to AEs? Just 3.9%, vs 10.2% in placebo.
No new safety signals. No psychosis worsening. Not perfect, but not the metabolic disaster zone we see with other agents.
🚀 What’s Next?
The FDA is reviewing this combo
For those of us treating chronic PTSD, this may be a real tool—not just a shiny new molecule with good marketing.
Until then, it’s worth paying attention. Because when sertraline alone doesn’t cut it—and we know it often doesn’t—this combo could offer a lifeline.
Leave a Reply